Company intelligence / Profile preview

Ardsley Pharmaceuticals

Waltham, Massachusetts, United Statesardsleyvillage.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Ardelyx has successfully commercialized two first-in-class medicines based on its proprietary research into gut transporters. IBSRELA® (tenapanor) treats irritable bowel syndrome with constipation and XPHOZAH® (tenapanor) addresses hyperphosphatemia in chronic kidney disease patients on dialysis. Both drugs are approved by the FDA. The company continues to advance additional candidates targeting renal and gastrointestinal diseases through its unique mechanism-of-action approach.

Therapeutic areas: GastroenterologyNephrology
Modalities: Small molecules (notably NHE3 inhibitors such as tenapanor)
Industry: Biotech

Partnerships

AstraZeneca—previous licensing/development partnership for tenapanor/RDX5791 program; AstraZeneca paid upfront/milestone payments but current status appears that rights reverted or were not fully outlicensed long-term.

Beyond the preview

Go deeper on Ardsley Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ardsley Pharmaceuticals.

Explore the full profile